ReviewCurrent opinion in ophthalmology2014
Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions.
Review in Current opinion in ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04676126 (Augmented Macular Pigment Supplement and Pericentral Visual Function), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Augmented Macular Pigment Supplement and Pericentral Visual Function: a Randomized Controlled Trial
Who cites it
24 citing papers in PubMed, 66 citations in OpenAlex.
- A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.Retina (Philadelphia, Pa.) · 2020Trial
- Tetrahedral DNA Framework Penetrating Ocular Barrier for Treatment of Retinal Oxidative Stress.ACS omega · 2025Article
- Current Advances in the Combination of Fatty Acids and Resveratrol to Fight Ocular Diseases.Molecular nutrition & food research · 2025Review
- Article
- HDL is the primary transporter for carotenoids from liver to retinal pigment epithelium in transgenic ApoA-IArchives of biochemistry and biophysics · 2022Article
- Pathogenic mechanisms contributing to the vulnerability of aging human photoreceptor cells.Eye (London, England) · 2021Review
- The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease.Translational vision science & technology · 2021Article
- Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.Drugs & aging · 2021Review
- Central retinal vein occlusion secondary to severe iron-deficiency anaemia resulting from a plant-based diet and menorrhagia: a case presentation.BMC ophthalmology · 2020Article
- Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.The British journal of ophthalmology · 2018Article
- RPE65 takes on another role in the vertebrate retina.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Nutritional Supplementation Inhibits the Increase in Serum Malondialdehyde in Patients with Wet Age-Related Macular Degeneration.Oxidative medicine and cellular longevity · 2017Article
- Absorption, metabolism, and functions of β-cryptoxanthin.Nutrition reviews · 2016Review
- Macular pigment optical density: repeatability, intereye correlation, and effect of ocular dominance.Clinical ophthalmology (Auckland, N.Z.) · 2016Article
- Norbixin Protects Retinal Pigmented Epithelium Cells and Photoreceptors against A2E-Mediated Phototoxicity In Vitro and In Vivo.PloS one · 2016Article
- Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
- [Supplements in age-related macular degeneration: recommendations by the German Ophthalmological Society, the German Retina Society and the German Professional Association of Ophthalmologists--October 2014].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2015Article
- Lutein Leads to a Decrease of Factor D Secretion by Cultured Mature Human Adipocytes.Journal of ophthalmology · 2015Article
- The Effect of Zeaxanthin on the Visual Acuity of Zebrafish.PloS one · 2015Article
- Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration.Cellular and molecular life sciences : CMLS · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis review provides a perspective on the Age-related Eye Disease Study 2 (AREDS2) including a summary of the goals and rationale of the study, major findings, subsequent management recommendations, and questions that remain to be answered. RECENT
findingsThe primary goal of the AREDS2 was to evaluate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 long-chain polyunsaturated acid supplementation in reducing the risk of developing advanced age-related macular degeneration (AMD). AREDS2 also investigated the effects of omitting β-carotene and reducing the concentration of zinc from the original AREDS formulation. Although primary analysis from the AREDS2 did not reveal a benefit of daily supplementation with lutein/zeaxanthin on AMD progression, secondary exploratory analyses suggested that lutein/zeaxanthin were helpful in reducing this risk. Comparison of low-dose to higher-dose zinc showed no significant benefit. SUMMARY: The overall evidence on the beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than β-carotene in AREDS-type supplements. Questions remain regarding the AREDS2 study results such as: whether the findings are generalizable to the population as a whole, what is the long-term safety profile of lutein/zeaxanthin supplementation, should other carotenoids be included in AREDS-type supplements, and at what optimal doses?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.